This 2005 report examines the issues surrounding the tenofovir trials and makes recommendations for ensuring that trials are carried out ethically and that provisions are made for dealing with the results of the trials when they are available. The report also calls for more concerted coordination and advance planning to accelerate evaluation, licensing, and access to PrEP.
Will a pill a day prevent HIV? Anticipating the results of the tenofovir “PrEP” trials
Ongoing and Planned PrEP Demonstration and Implementation Studies
This is a summary table of ongoing and planned global PrEP evaluation studies.
US CDC Releases New Clinical Guidelines for PrEP
The guidelines, the first national guidelines for PrEP use, provide instructions for health providers about providing daily TDF/FTC as PrEP for individuals at “substantial risk for HIV infection”; visit PrEP Watch to learn more about the guidelines, download materials and more.
And a group of 164 leading HIV/AIDS and health organizations today reiterated their strong support for oral PrEP as an important HIV prevention strategy for men and women at risk of HIV infection. The diverse group of advocates, researchers and service providers hailed new HIV PrEP guidelines from the US Centers for Disease Control and Prevention (CDC) as a science-driven, public health approach to what remains a major health crisis in the United States.
AIDS Vaccine Science for Busy Advocates – Current AIDS Vaccine R&D Pipeline
One-pager reviewing what we’ve learned from previous efficacy trials, the product pipeline and where we are today and future directions toward finding a vaccine that works.
Pre-Exposure Prophylaxis: An introductory factsheet
This introductory 2-page document defines PrEP, reviews the scientific evidence to date, and outlines key research, regulatory and advocacy issues going forward. This factsheet is part of a series on emerging HIV prevention strategies.
PrEP Primer (Chinese)
This document, developed by 2012 AVAC Advocacy Fellow Cai Lingping, provides background information on pre-exposure prophylaxis, reviews the evidence base and planned trials, and discusses key issues for Chinese advocates. It explores implementation challenges and the funding landscape for continued research.
Online CHAIN MSM Survey: Willingness and influencing factors for usage of PrEP among MSM
This study of 760 men who have sex with men in China, conducted by 2013 AVAC Advocacy Fellow Cai Lingping, finds high acceptability of pre-exposure prophylaxis. The survey also assessed how well informed respondents were about PrEP and examined factors that would make them more or less willing to take it.
HIV Civil Society Recommendations for Kenya’s New Health Secretary and Global Fund Application
This letter, written by a civil society coalition co-led by 2013 AVAC Advocacy Fellow Maureen Milanga, summarizes concerns and demands related to Kenya’s 2013 application to the Global Fund. The letter was sent during the Global Fund’s transition to its New Funding Model and includes guidance to the Government of Kenya on how to navigate the new system to secure support for ambitious treatment scale-up in the wake of new WHO treatment guidelines.
The Change We Need to End AIDS in Uganda: A civil society analysis of the state of Uganda’s AIDS response
This document, developed by a coalition of civil society groups co-led by AVAC Advocacy Fellows Alice Kayong-Mutebi, Richard Hasunira and Sylvia Nakasi, identifies failures in the Ugandan AIDS response and a 10-point plan to end the country’s epidemic.
Letter to Ambassador Goosby on PEPFAR and the national response to HIV in Uganda in 2012-13
This letter, written by a coalition of civil society groups co-led by AVAC Advocacy Fellows Alice Kayong-Mutebi, Richard Hasunira and Sylvia Nakasi, summarizes concerns and demands related to the US PEPFAR program’s 2012 Country Operating Plan. A country operating plan dictates the scope, funding levels and targets of PEPFAR programming on an annual basis.